- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-4 Registration of securities issued in business combination transactions
- 3.1 EX-3.1
- 3.3 EX-3.3
- 8.1 EX-8.1
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.2 EX-99.2
- 99.3 EX-99.3
- 99.4 EX-99.4
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- EX-FILING FEES Ex-filing Fees
- 15 Feb 24 25-NSE Exchange delisting
- 9 May 22 425 Business combination disclosure
- 27 Apr 22 425 Business combination disclosure
- 19 Apr 22 425 Business combination disclosure
- 18 Apr 22 425 Business combination disclosure
- 18 Apr 22 425 Business combination disclosure
- 18 Apr 22 EFFECT Notice of effectiveness
- 15 Apr 22 424B3 Prospectus supplement
- 11 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 6 Apr 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 Mar 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
8 Mar 22 S-4 Registration of securities issued in business combination transactions
- 11 Apr 22 Registration of securities issued in business combination transactions (amended)
- 6 Apr 22 Registration of securities issued in business combination transactions (amended)
- 25 Mar 22 Registration of securities issued in business combination transactions (amended)
- 8 Mar 22 Registration of securities issued in business combination transactions
Exhibit 99.4
Consent to be Named as a Director
March 7, 2022
Comera Life Science Holdings, Inc.
12Gill Street
Suite 4650
Woburn, Massachusetts 01801
Comera Life Science Holdings, Inc. is filing a Registration Statement on Form S-4 (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus included in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of the Company following the consummation of the business combination as described in the proxy statement/prospectus. I also consent to the filing of this consent as an exhibit to the Registration Statement and any amendments thereto.
| Sincerely, |
| Kirsten Flowers |
| (Name) |
| /s/ Kirsten Flowers |
| (Signature) |